# Innovita Biological Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovita-biological-technology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.innovita.com.cn
- Latest round: Series B (Dec 3, 2018)
- Investors on record: 6

## About

Based in Beijing, China and established in 2006, Innovita Biological Technology Co., Ltd. is a technology company that focuses on the development, production and sales of POCT in vitro diagnostic products. In 2010, the company participated in the formulation of national standards for prenatal and postnatal care testing. In 2015, the company successfully registered respiratory detection products. In 2022, the company was listed on the Shanghai Stock Exchange. Its stock code is 688253.

The company's main products include automatic colloidal gold immunochromatography analyzer, triple inspection of respiratory antigens and novel coronavirus (2019-nCoV) antigen detection kits, etc. The fully automatic colloidal gold immunochromatography analyzer is used in conjunction with the appropriate specific reagents based on colloidal gold immunochromatography for quantitative and qualitative analysis of analytes in human samples. The company's products are used in respiratory, cardiovascular and renal function testing fields.

## Funding rounds

- Series B, Dec 3, 2018 — YuanBio Venture
- Series A, Dec 1, 2015 — Qin'an Capital, Zhonghao Shengtuo Investment, Ganghong Investment Management, Da'an Jinghan Capital, Ansheng Investment

## Investors

- Qin'an Capital (https://capitalatlas.ai/funds/qin-an-capital) — Series A
- Zhonghao Shengtuo Investment — Series A
- Ganghong Investment Management — Series A
- Da'an Jinghan Capital (https://capitalatlas.ai/funds/da-an-jinghan-capital) — Series A
- Ansheng Investment — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series B